ChromaDex, Inc. Reports Second Quarter 2010 Financial Results

IRVINE, Calif., Aug. 17 /PRNewswire-FirstCall/ -- ChromaDex Corporation, (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, today announced financial results for the second quarter of 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.01 per share for the thirteen week period ended July 3, 2010.

As of July 3, 2010, cash, cash equivalents, and marketable securities totaled $3,381,744.

"ChromaDex is continuing to position ourselves to take advantage of the unique product offerings we have acquired and will continue to develop novel ingredients for dietary supplement, food and related industries," said Frank Jaksch, CEO and co-founder of ChromaDex. "By continuing to license technology that ChromaDex believes has a strong future potential to be marketed to many industry segments, we will be able to offer our customers and consumers significant new options in the field of natural products."

Additional Financial Results & Notes

On a reported basis, ChromaDex recorded revenue during the second quarter of 2010 of $2,033,861 as compared to $1,342,716 for the same period in 2009. The net loss attributable to common stockholders for the thirteen weeks ended July 3, 2010, was $303,529 as compared to a net loss of $291,100 for the same period in 2009. The net loss in the second quarter of 2010 was attributable an increase in share based compensation expenses of $230,858 as compared to a $50,830 versus the same period in 2009, and an adoption of a formal investor relations program to increase market and shareholder awareness.

About ChromaDex

ChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards. Among other things, the Company is currently focusing on clinical studies and the commercialization of its new product, pTeroPure pterostilbene ( as a result of its exclusive worldwide patent rights for pterostilbene. For more information, visit or follow ChromaDex on Twitter @ChromaDex.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Investor Inquiries

Liviakis Financial Communications, Inc.

John M. Liviakis, President


ChromaDex Contact

Jenny Robles

Administrative Assistant to the CEO

10005 Muirlands Blvd, Suite G, Irvine, CA 92618


Media Contact

Megan Lavine

Canale Communications

3033 5th Ave., Suite 400, San Diego, CA 92103


ChromaDex Corporation and Subsidiaries

Consolidated Statements of Operations (Unaudited)

For the Three Month Periods ended

Three Months Ended

July 3, 2010

July 4, 2009


$ 2,033,861

$ 1,342,716

Cost of sales



Gross profit



Operating expenses:

Sales and marketing



General and administrative





Operating loss



Nonoperating (income) expenses:

Interest expense



Interest income





Net loss

$ (303,529)

$ (291,100)

Basic and Diluted loss per common share

$ (0.01)

$ (0.01)

Basic and Diluted average common shares outstanding



See Notes to Consolidated Financial Statements.

SOURCE ChromaDex Corporation

Back to news